Ella (Ulipristal Acetate) - Summary

ELLA SUMMARY

The ella (ulipristal acetate) tablet for oral use contains 30 mg of a single active steroid ingredient, ulipristal acetate [17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione], a synthetic progesterone agonist/antagonist.

ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella is not intended for routine use as a contraceptive.

See all Ella indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Ella (Ulipristal)

Astellas, Vical Herpes Vaccine Fails Mid-stage Study
Source: Medscape Transplantation Headlines [2016.09.20]
Japan's Astellas Pharma Inc and San Diego-based Vical Inc said their experimental herpes vaccine failed a mid-stage study involving certain kidney transplant patients.
Reuters Health Information

Chickenpox (Varicella)
Source: MedicineNet Immunizations Specialty [2016.09.08]
Title: Chickenpox (Varicella)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 9/8/2016 12:00:00 AM

New types of African Salmonella associated with lethal infection
Source: Tropical Diseases News From Medical News Today [2016.08.24]
The first global-scale genetic study of Salmonella Enteritidis bacteria, which is a major cause of blood poisoning and death in Africa and food poisoning in the Western World, has discovered that...

Zika Infants May Have Constellation of Brain Abnormalities (CME/CE)
Source: MedPage Today Radiology [2016.08.23]
(MedPage Today) -- Imaging shows abnormalities beyond microcephaly

Health Tip: Learn About Salmonella
Source: MedicineNet Food Poisoning Specialty [2016.08.10]
Title: Health Tip: Learn About Salmonella
Category: Health News
Created: 8/10/2016 12:00:00 AM
Last Editorial Review: 8/10/2016 12:00:00 AM

more news >>

Published Studies Related to Ella (Ulipristal)

Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. [2013]
N-mono-demethylated metabolite, PGL4002, were investigated in women... CONCLUSION: Daily administration of UPA at therapeutic and

Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. [2010.02.13]
BACKGROUND: Emergency contraception can prevent unintended pregnancies, but current methods are only effective if used as soon as possible after sexual intercourse and before ovulation. We compared the efficacy and safety of ulipristal acetate with levonorgestrel for emergency contraception... INTERPRETATION: Ulipristal acetate provides women and health-care providers with an effective alternative for emergency contraception that can be used up to 5 days after unprotected sexual intercourse. FUNDING: HRA Pharma. Copyright 2010 Elsevier Ltd. All rights reserved.

Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. [2010]
mm... CONCLUSIONS: This study demonstrates that UPA can significantly delay follicular

Randomised comparison of the FerX Ella antireflux stent and the ultraflex stent: proton pump inhibitor combination for prevention of post-stent reflux in patients with esophageal carcinoma involving the esophago-gastric junction. [2008.05]
BACKGROUND AND AIM: Metal stents placed across the gastroesophageal junction in patients with malignant dysphagia frequently present with reflux symptoms. We compared an antireflux stent with a standard open stent used in combination with proton pump inhibitor medication... CONCLUSION: The antireflux stent had no demonstrable advantages compared to the combination of standard open stent and proton pump inhibitor medication.

[Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women]. [Article in Polish] [2013]
Uterine leiomyomata (fibroids) are very common, mostly benign tumors in women of reproductive age... The presented results on the application UPA in the medical treatment of symptomatic uterine fibroids are very promising and gynecologists are given a new treatment option.

more studies >>

Clinical Trials Related to Ella (Ulipristal)

Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella [Recruiting]
The study is aimed at assessing the clinical follow-up and the outcomes of pregnancies exposed to ella, whether due to failure of the emergency contraception or inadvertent exposure during pregnancy.

Ulipristal for Endometriosis-related Pelvic Pain [Recruiting]
The aim of this research is to assess the benefit of a medication (ulipristal) for alleviation of symptoms in women with chronic, endometriosis-related pelvic pain.

Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914 [Completed]
This study will evaluate whether the experimental drug ulipristal acetate can shrink uterine fibroids in pre-menopausal women.

Ulipristal Emergency Contraception Used Before or After Ovulation [Completed]
This was a prospective, open-label, single-drug, uncontrolled, observational clinical study. Women attending the Family Planning Association of Hong Kong (FPAHK) for emergency contraception within 120 hours of UPSI were recruited. Subjects were recruited from both the Birth Control Clinics and Youth Health Care Centres of the FPAHK. Depending on the timing in relation to ovulation in the current menstrual cycle at the time of presentation, the women were classified into two groups: Group 1: pre-ovulatory Group 2: post-ovulatory After counseling and obtaining informed consent, eligible subjects received a single dose of ulipristal acetate 30 mg (ellaOne®) under direct supervision. A baseline blood test for hormonal profile (LH, oestradiol and progesterone) and ultrasound scan for ovarian follicle assessment were carried out by a designated doctor or research nurse at the clinic visit. The subjects were advised not to have further acts of coitus before the return of menstruation. They were given a diary chart to record vaginal spotting and bleeding, possible side effects and further acts of intercourse, if any, and the contraceptive method used. A follow-up appointment were be arranged about 1-2 weeks after the expected next menstruation. Any events of unplanned pregnancy and adverse effects were recorded for analysis.

SX ELLA Esophageal Degradable BD Stent System [Completed]

more trials >>

Reports of Suspected Ella (Ulipristal) Side Effects

Unintended Pregnancy (4),  Maternal Exposure During Pregnancy (3),  Drug Ineffective (2),  Thirst (2),  DRY Mouth (2),  Drug Prescribing Error (2),  Drug Interaction (1),  Pregnancy After Post Coital Contraception (1),  Menstrual Disorder (1),  Menstruation Irregular (1), more >>